Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Share-based Compensation (2020 - 2025)

Insight Molecular Diagnostics' Share-based Compensation history spans 6 years, with the latest figure at $521000.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation rose 15.78% year-over-year to $521000.0; the TTM value through Sep 2025 reached $2.0 million, up 14.9%, while the annual FY2024 figure was $1.8 million, 36.49% down from the prior year.
  • Share-based Compensation for Q3 2025 was $521000.0 at Insight Molecular Diagnostics, up from $504000.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $3.2 million in Q3 2022 and bottomed at $386000.0 in Q2 2024.
  • The 5-year median for Share-based Compensation is $834000.0 (2023), against an average of $1.2 million.
  • The largest annual shift saw Share-based Compensation surged 73.27% in 2021 before it crashed 81.52% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $1.7 million in 2021, then skyrocketed by 53.61% to $2.6 million in 2022, then plummeted by 81.52% to $484000.0 in 2023, then grew by 3.1% to $499000.0 in 2024, then grew by 4.41% to $521000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Share-based Compensation are $521000.0 (Q3 2025), $504000.0 (Q2 2025), and $473000.0 (Q1 2025).